SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.View the full article
Yahoo- Neurocrine Advances VMAT2 Inhibitor Program (redOrbit)
1 - 1 of 1 Posts
1 - 1 of 1 Posts
- This is an older thread, you may not receive a response, and could be reviving an old thread. Please consider creating a new thread.
Irritable Bowel Syndrome and Digestive Health Support Forum
A forum community dedicated to Irritable Bowel Syndrome and Digestive Health Support. Come join the discussion about treatment, diet, health, lifestyles, spirituality, medication, research, recovery, and more!
Full Forum Listing
Recommended Communities
Join now to ask and comment!
